2013 American Transplant Congress
All-Trans Retinoic Acid and Rapamycin Synergize with Transforming Growth Factor-β To Induce Regulatory T Cells but Confer Distinct In Vivo Migratory Capacities
University of Pittsburgh, Pittsburgh; Massachusetts Institute of Technology, Cambridge
Therapies based on regulatory T cells (Treg) hold great promise for promotion of transplant tolerance. Additionally, recent insights in Treg function have underscored the importance…2013 American Transplant Congress
Comparison of Health Status and Quality of Life of Related Versus Paid Unrelated Living Kidney Donors: A Single Center Experience from Iran
In Iran, the unrelated living kidney donors (LKDs) are financially reimbursed by the government as well as the transplant recipients, a practice legal in the…2013 American Transplant Congress
Evolution of SPK Transplant in Type I and Type II Diabetics with End Stage Renal Disease: The 20 Year Experience, The
Surgery, Washington Hospital Center, Washington, DC
Introduction: There continues to be much debate whether Type II diabetics can benefit from a SPK. We are reporting our 20 years experience in patients…2013 American Transplant Congress
Risk Factors Associated with Surgical Complications in Recipients of Kidneys from Very Small Pediatric Donors
UC Davis Transplant Center, Sacramento, CA
Transplantation of kidneys from very small pediatric donors is associated with a high rate of surgical complications and graft loss. We examined our series of…2013 American Transplant Congress
Pronounced Impact of Community Risk Factors on Pre-Transplant Kidney Candidate Processes and Outcomes
IntroductionThere are many potential factors which are associated with patient outcomes beyond traditional clinical and donor characteristics.MethodsWe merged national SRTR data with data aggregated from…2013 American Transplant Congress
Network Meta-Analysis of Immunosuppressant Regimens in Renal Preservation Following Liver Transplant, A
Background: Long-term exposure to Calcineurin-Inhibitors (CNIs) has been associated with impaired renal function.Objective: To obtain parameter estimates of the relative renal safety of commonly used…2013 American Transplant Congress
Kidney Transplant Volume and Outcomes Trends in the Era Surrounding Initiation of the Medicare Conditions of Participation
Background: In mid-2007, the Centers for Medicare and Medicaid Services (CMS) implemented Conditions of Participation for organ transplant programs, under which programs not attaining specified…2013 American Transplant Congress
Eculizumab (Anti-C5) for Treatment of Severe Antibody-Mediated Rejection (ABMR) and Recurrent C3 Glomerulonephritis in Renal Allografts: A Single Center Experience
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
INTRODUCTION: ABMR is a severe form of allograft injury mediated, primarily, by antibody-induced complement activation. Complement activation through the alternate pathway may also result in…2013 American Transplant Congress
Long-Term Calcineurin Inhibitor (CNI) and Corticosteroid (CS) Avoidance Using Belatacept: The CTOT-10 Experience
Emory Transplant Center; Univ of Alabama-Birmingham; UC-San Francisco; NIAID/NIH; Rho
Belatacept is approved a component of a CNI-free immunosuppressive regimen in EBV + adults undergoing renal transplantation. The intent of this NIH-sponsored CTOT study was…2013 American Transplant Congress
Decreased Rejection and Equivalent Survival with Selective Alemtuzumab Induction for Renal Transplantation
University of Maryland School of Medicine, Baltimore, MD
Selective immunosuppressive therapies based on donor and recipient factors should minimize rejection and optimize patient and graft outcomes. We developed in 2006 a selective algorithm…
American Transplant Congress abstracts